Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TGM1 | P22735 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3335937 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL3822619 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL3058628 | 0.87 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL14964692 | 0.87 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL30993374 | 0.85 | HTR2C (0.62) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL6094897 | 0.85 | HTR2C (0.62) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL31288321 | 0.85 | HTR2C (0.62) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL13156576 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| Hydrochloric Acid SCHEMBL19742033 | 0.83 | HTR2C (0.60) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 | |
| SCHEMBL3717717 | 0.83 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9AHTR2CMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796297-B2 | 4-substituted-2-amino-pyrimidine derivatives | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796297-B2 | 4-substituted-2-amino-pyrimidine derivatives | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| US-7951791-B2 | e.g. 2,7-bis-[(3R)-1-azabicyclo[2.2.2]octan-3-yloxy]-fluoren-9-one; alpha 7 Nicotinic acetylcholine receptors ligands; cognitive disorder, neurodegeneration, and neurodevelopmental disorders | ABBOTT LABORATORIES (US) | 2011-05-31 | — | — | US | disclosed |
| US-20100331294-A1 | 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331294-A1 | 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2258682-A2 | Amino-substituted tricyclic derivatives and methods of use | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-7365193-B2 | Amino-substituted tricyclic derivatives and methods of use | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1711463-A2 | AMINO-SUBSTITUTED TRICYCLIC DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | ABBVIE INC. | 2005-10-20 | — | — | US | disclosed |
| WO-2005077899-A2 | AMINO-SUBSTITUTED TRICYCLIC DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | CHRNA1, CHRM1, GALR1 | SMN1; SMN2 1026/4885NPC1 927/4885RAB9A 3118/4885 |
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | SMN1; SMN2 2135/4885NPC1 380/4885RAB9A 1279/4885 |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | CHRNA1, CHRM1, CHRNB1 | SMN1; SMN2 701/4885NPC1 1584/4885RAB9A 2877/4885 |
| US-20100331294-A1 | 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES | HRH2, HRH4, HRH3 | SMN1; SMN2 2514/4885NPC1 2553/4885RAB9A 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.